S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
S&P 500   4,960.48 (-1.01%)
DOW   37,914.86 (+0.37%)
QQQ   414.27 (-2.16%)
AAPL   164.93 (-1.26%)
MSFT   399.46 (-1.19%)
META   480.21 (-4.30%)
GOOGL   153.68 (-1.49%)
AMZN   173.91 (-2.96%)
TSLA   147.04 (-1.93%)
NVDA   771.66 (-8.86%)
AMD   145.95 (-5.89%)
NIO   3.81 (-4.75%)
BABA   69.04 (+0.23%)
T   16.51 (+1.10%)
F   12.08 (+0.17%)
MU   106.25 (-5.07%)
GE   148.23 (-3.08%)
CGC   7.96 (+1.66%)
DIS   112.17 (-0.23%)
AMC   3.18 (+8.90%)
PFE   25.93 (+2.13%)
PYPL   61.76 (-0.55%)
XOM   119.81 (+1.09%)
Free Trial
ASX:PAR

Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free PAR Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.81 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
PAR stock logo

About Paradigm Biopharmaceuticals Stock (ASX:PAR)

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

PAR Stock News Headlines

April 19, 2024 | msn.com
Paradigm Signs ‘Fire Island’ & ‘How To Get Away With Murder’ Actor Conrad Ricamora
April 19, 2024 | msn.com
Paradigm makes key submission to US FDA to advance osteoarthritis Phase 3 trial
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
April 17, 2024 | msn.com
Sheboygan jazz masterclass at Paradigm will feature Milwaukee Jazz Institute's managing director
April 9, 2024 | msn.com
WWE Star Damian Priest Signs With Paradigm (EXCLUSIVE)
April 9, 2024 | benzinga.com
Monad Labs Raises $225 Million in Funding Round Led by Paradigm
April 9, 2024 | sg.style.yahoo.com
10 best makan places in Paradigm Mall JB
April 4, 2024 | msn.com
Reggie Bush Signs With Paradigm Talent Agency In All Areas, Launches Production Company
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
April 2, 2024 | msn.com
Merkle Achieves $1 Billion Valuation with Paradigm Leading Funding Surge
March 27, 2024 | msn.com
Paradigm Signs ‘Red, White & Royal Blue’ Breakout Taylor Zakhar Perez
March 20, 2024 | msn.com
Lit Agents Alysia Thomas, Kelsey Roberts Exit Paradigm
March 19, 2024 | uk.movies.yahoo.com
Paradigm Hires Verve Alums Bill Weinstein, Devon Schiff As Lit Agents
March 19, 2024 | msn.com
Bill Weinstein Joins Paradigm Talent Agency Following Verve Exit
March 19, 2024 | msn.com
Bill Weinstein & Paradigm At The Altar? – The Dish
March 18, 2024 | msn.com
Ocugen's Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon
March 13, 2024 | finance.yahoo.com
Shift Paradigm acquires design and technology consultancy Principle Studios
March 11, 2024 | msn.com
Monad Labs in talks to raise more than $200 million round led by Paradigm, valuing the Jump Crypto–linked startup at $3 billion
February 29, 2024 | tmcnet.com
Paradigm by Puloli™ Announces Customers in Eagle Ford
February 27, 2024 | msn.com
Jaime King Signs With Paradigm
February 27, 2024 | msn.com
What’s in store for 2024: Paradigm Biopharmaceuticals
February 23, 2024 | tmcnet.com
Global Disinfection Robots Market Report 2024: Analysis of Funding and Investments for Developing Disinfection Robots
February 22, 2024 | yahoo.com
Paradigm Hires Kyle Jensen and Jamie Kaye-Phillips, Promotes Matthew Nutty, Taps Brian Neal for Napoli Management Group
February 20, 2024 | msn.com
ASX stocks striving to inject youthfulness into an aging world population
February 14, 2024 | bloomberg.com
Paradigm’s Famed ‘White-Hat’ Hacker Unites Peers Against Crypto Attacks
February 11, 2024 | finance.yahoo.com
Paradigm Biopharmaceuticals Limited (ASX:PAR) Is Expected To Breakeven In The Near Future
February 8, 2024 | morningstar.com
Paradigm Biopharmaceuticals Ltd PAR
See More Headlines
Receive PAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:PAR
CUSIP
N/A
CIK
N/A
Web
www.paradigmbiopharma.com
Phone
61 3 9629 5566
Fax
N/A
Employees
1,031
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,000,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-128.42%
Return on Assets
-72.47%

Debt

Debt-to-Equity Ratio
0.86
Current Ratio
3.83
Quick Ratio
5.93

Sales & Book Value

Annual Sales
$79,224.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
6.44
Book Value
A$0.10 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
351,200,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.92
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Paul John Rennie BSc (Age 65)
    Grad Dip, MBM, MSTC, Founder, MD & Executive Chairman
    Comp: $1.75M
  • Dr. Donna L. Skerrett M.D. (Age 67)
    MS, Chief Medical Officer and Executive Director
    Comp: $1.26M
  • Ms. Abby Macnish Niven B.Com.
    B.Sc., C.F.A., Interim Company Secretary & Interim CFO
  • Dr. Ravi Krishnan
    Chief Scientific Officer
  • Mr. Simon White
    Director of Investor Relations
  • Dr. Michael Imperiale
    Global Head of Drug Safety & MPS
  • Ms. Beverley Huttmann
    Commercial Head
  • Ms. Michelle Coffey
    Global Head of Regulatory Affairs
  • Dr. Mukesh Ahuja
    Global Clinical Head of OA

Key Competitors

View All Competitors

Insiders


PAR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Paradigm Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), First Graphene (FGR), Envirosuite (EVS), Bubs Australia (BUB), Blue Energy (BLU), BHP Group (BHP), Alcidion Group (ALC), a2 Milk (A2M) and 8common (8CO).

This page (ASX:PAR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press